Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

ival (p = 0.0018) favoring nimotuzumab. The addition of nimotuzumab did not add to the toxicities of either regimen, with no Grade III/IV skin toxicities observed. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab.

YM BioSciences today posted a series of documents on its website, www.ymbiosciences.com that address frequently asked questions made by the investment community and pharmaceutical industry relating to YM's products and business strategy. A comprehensive description of the completed and ongoing trials being conducted by YM and the other licensees of nimotuzumab is also available at YM's website.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 ... Market Research "Quantum Dots Market - Global Industry Analysis, ... the market was valued at USD 88.5 million in ... by 2023, growing at a CAGR of 53.8% from ... Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... of New York City, partnered with GI Energy, one of ... to complete a $13 million upgrade of its 43-year-old CHP ... in 1971 and in an effort to extend the life ... of six generators and associated electrical and heat recovery equipment, ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading provider ... today announced that it will hold an investor conference ... financial results for the first quarter of fiscal 2015 ... the current fiscal year. , The dial-in number for ... 2014, at 5 p.m. EDT (2 p.m. PDT) is ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 /PRNewswire/ ... of an Irys™System by BGI , ... to enable comprehensive exploration of human structural variation (SV) ... of interest, including those where no reference exists. In ... new methods for multiplexing on the Irys System, enabling ...
Breaking Biology Technology:Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:8/1/2014)... The Journal of Nutrition Education and Behavior (JNEB) announces ... (GEM) awards, which were presented at the Society for ... Impact: Local to Global," in Milwaukee, Wisconsin, June 28 ... the authors of the best article and best GEM ... of the JNEB Journal Committee and Board of Editors. ...
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
... international research team co-led by a scientist at Fred ... behind the third most common form of muscular dystrophy. ... represent the latest in the team,s series of groundbreaking ... facioscapulohumeral muscular dystrophy, or FSHD., The team, co-led by ...
... geneticists sheds new light on how Facioscapulohumeral Muscular Dystrophy ... commonly known as FSHD, the devastating disease affects both ... inherited genetic disorder, yet sometimes appears spontaneously via new ... condition. "People with the condition experience progressive ...
... 2012 - Jackson Hole, Wyoming Scientists believe that ... primary genetic material, early,forms of life used RNA to ... life,rely on before RNA? The answer may be ... a hypothetical,backbone for Peptide Nucleic Acids, which have been ...
Cached Biology News:Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 3Weber State Scientists discover possible building blocks of ancient genetic systems 2
...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
... utility and flexibility press-to-seal silicone isolators can ... the researcher. They are available either pre-cut ... material that can be easily trimmed to ... and non-cytotoxic and can be used to ...
... the mycobacteria found in Complete Freund's Adjuvant so ... Freund's Adjuvant is used for ... to produce water-in-oil emulsions of immunogens. ... antibody responses which can be attributed to the ...
Biology Products: